HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 66.3%

Neg 0% Neu 0% Pos 66.3%

HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $33 to $35.